Breaking News

Plant-Based COVID-19 Vaccine Flourishes

December 7, 2021 • 9:38 am CST
(Precision Vaccinations)

England-based Medicago and GlaxoSmithKline (GSK) today announced positive results from the global Phase 3 placebo-controlled efficacy study of Medicago's plant-based COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant, conducted across six countries.

The overall vaccine efficacy rate against all variants of SARS-COV-2 was 71%. And the Omicron variant was not circulating during this study.

Medicago will imminently seek regulatory approval from Health Canada as part of its rolling submission based on these results.

However, the vaccine candidate is not approved yet by any regulatory authorities.

Thomas Breuer, GSK's global COVID-19 adjuvanted vaccines lead and Chief Global Health Officer, said in a press release, "These are encouraging results given data were obtained in an environment with no ancestral virus circulating."

"The global COVID-19 pandemic is continuing to show new facets with the current dominance of the Delta variant, upcoming Omicron and other variants likely to follow."

"The combination of GSK's established pandemic adjuvant with Medicago's plant-based vaccine technology has significant potential to be an effective, refrigerator-stable option to help protect people against SARS-CoV-2."

Medicago has been developing its plant-based technology for the past 20 years, using unique technology to produce Virus-Like Particles (VLP) for its protein vaccines.

VLPs are designed to mimic the native structure of viruses, allowing them to be easily recognized by the immune system. In addition, because the VLPs lack core genetic material, they are non-infectious and unable to replicate.

Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation. For more information:

Medical Review by